[go: up one dir, main page]

TWI478929B - 含2,5,7-經取代唑并嘧啶環之羧酸衍生物 - Google Patents

含2,5,7-經取代唑并嘧啶環之羧酸衍生物 Download PDF

Info

Publication number
TWI478929B
TWI478929B TW100100890A TW100100890A TWI478929B TW I478929 B TWI478929 B TW I478929B TW 100100890 A TW100100890 A TW 100100890A TW 100100890 A TW100100890 A TW 100100890A TW I478929 B TWI478929 B TW I478929B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
phenoxy
ring
dimethyl
Prior art date
Application number
TW100100890A
Other languages
English (en)
Chinese (zh)
Other versions
TW201136940A (en
Inventor
Dieter Kadereit
Matthias Schaefer
Stephanie Hachtel
Axel Dietrich
Thomas Huebschle
Andreas Gille
Katrin Hiss
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW201136940A publication Critical patent/TW201136940A/zh
Application granted granted Critical
Publication of TWI478929B publication Critical patent/TWI478929B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW100100890A 2010-01-13 2011-01-11 含2,5,7-經取代唑并嘧啶環之羧酸衍生物 TWI478929B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305036 2010-01-13

Publications (2)

Publication Number Publication Date
TW201136940A TW201136940A (en) 2011-11-01
TWI478929B true TWI478929B (zh) 2015-04-01

Family

ID=42111309

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100100890A TWI478929B (zh) 2010-01-13 2011-01-11 含2,5,7-經取代唑并嘧啶環之羧酸衍生物

Country Status (20)

Country Link
US (1) US8748436B2 (es)
EP (1) EP2523958B1 (es)
JP (1) JP5844277B2 (es)
KR (1) KR101759117B1 (es)
CN (1) CN103097392B (es)
AR (1) AR079981A1 (es)
AU (1) AU2011206613B2 (es)
BR (1) BR112012017485A2 (es)
CA (1) CA2799474C (es)
DK (1) DK2523958T3 (es)
ES (1) ES2453956T3 (es)
IL (1) IL220706A (es)
MX (1) MX2012007870A (es)
MY (1) MY156960A (es)
PT (1) PT2523958E (es)
RU (1) RU2560876C2 (es)
SG (1) SG182477A1 (es)
TW (1) TWI478929B (es)
UY (1) UY33177A (es)
WO (1) WO2011086077A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079980A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
RS53254B (sr) * 2010-01-14 2014-08-29 Sanofi Derivati karboksilne kiseline sa 2,5-supstituisanim oksazolopirimidinskim prstenom
AU2011206617B2 (en) * 2010-01-14 2015-07-16 Sanofi 2,5-substituted oxazolopyrimidine derivatives
EP2523960B1 (de) * 2010-01-14 2013-10-16 Sanofi Heterocyclische carbonsäurederivate mit einem 2,5-substituierten oxazolopyrimidinring
US9321787B2 (en) 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
EP2990055B1 (en) 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000833A1 (en) * 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
WO2009154775A1 (en) * 2008-06-20 2009-12-23 Amgen Inc. S1p1 receptor agonists and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679682A (en) * 1970-04-23 1972-07-25 Fmc Corp CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES
MXPA05010802A (es) 2003-04-25 2005-12-14 Univ Cardiff Compuestos heterociclicos para el uso en el tratamiento de infecciones virales.
PL1638551T3 (pl) * 2003-05-19 2012-05-31 Irm Llc Związki i kompozycje immunosupresyjne
EP1965807A4 (en) * 2005-11-23 2010-10-27 Epix Delaware Inc S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE
JP5191497B2 (ja) * 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ,インコーポレイテッド S1p受容体調節化合物およびその使用
JP5449346B2 (ja) 2008-07-15 2014-03-19 サノフイ Edg−1受容体アゴニストとしてのオキサゾロピリミジン類
RS53254B (sr) 2010-01-14 2014-08-29 Sanofi Derivati karboksilne kiseline sa 2,5-supstituisanim oksazolopirimidinskim prstenom
AU2011206617B2 (en) 2010-01-14 2015-07-16 Sanofi 2,5-substituted oxazolopyrimidine derivatives
EP2523960B1 (de) 2010-01-14 2013-10-16 Sanofi Heterocyclische carbonsäurederivate mit einem 2,5-substituierten oxazolopyrimidinring

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000833A1 (en) * 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
WO2009154775A1 (en) * 2008-06-20 2009-12-23 Amgen Inc. S1p1 receptor agonists and use thereof

Also Published As

Publication number Publication date
HK1180314A1 (en) 2013-10-18
KR101759117B1 (ko) 2017-07-18
EP2523958A1 (de) 2012-11-21
PT2523958E (pt) 2014-03-27
JP5844277B2 (ja) 2016-01-13
AU2011206613A1 (en) 2012-08-02
KR20120115397A (ko) 2012-10-17
US8748436B2 (en) 2014-06-10
CA2799474A1 (en) 2011-07-21
TW201136940A (en) 2011-11-01
BR112012017485A2 (pt) 2016-04-19
IL220706A (en) 2015-06-30
CN103097392B (zh) 2015-05-13
CA2799474C (en) 2018-02-20
RU2560876C2 (ru) 2015-08-20
WO2011086077A1 (de) 2011-07-21
AR079981A1 (es) 2012-03-07
RU2012134378A (ru) 2014-02-20
MY156960A (en) 2016-04-15
CN103097392A (zh) 2013-05-08
SG182477A1 (en) 2012-08-30
JP2013517239A (ja) 2013-05-16
IL220706A0 (en) 2012-08-30
DK2523958T3 (da) 2014-03-31
US20130079357A1 (en) 2013-03-28
AU2011206613B2 (en) 2015-04-02
EP2523958B1 (de) 2013-12-25
MX2012007870A (es) 2012-07-25
UY33177A (es) 2011-08-31
ES2453956T3 (es) 2014-04-09

Similar Documents

Publication Publication Date Title
TWI485153B (zh) 2,5,7-經取代唑并嘧啶衍生物
TWI478929B (zh) 含2,5,7-經取代唑并嘧啶環之羧酸衍生物
KR101759128B1 (ko) 2,5-치환된 옥사졸로피리미딘 환을 갖는 카복실산 유도체
CN102834399B (zh) 具有2,5-取代的*唑并嘧啶环的杂环羧酸衍生物
JP5844278B2 (ja) 2,5,7−置換されたオキサゾロピリミジン環を有する複素環式カルボン酸誘導体
CN103797015B (zh) 具有噁唑并[5,4-d]嘧啶环的羧酸衍生物
HK1180314B (en) Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees